Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.

被引：5
|
作者：
Le, Xiuning
Goldman, Jonathan Wade
Clarke, Jeffrey Melson
Tchekmedyian, Nishan
Piotrowska, Zofia
Chu, David
Bhat, Gajanan
Lebel, Francois M.
Socinski, Mark A.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[2] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA
[3] Duke Canc Inst, Durham, NC USA
[4] Pacific Shores Med Grp, Long Beach, CA USA
[5] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[6] North Shore Hematol Oncol Associates, East Setauket, NY USA
[7] Spectrum Pharmaceut, Irvine, CA USA
[8] AdventHlth Canc Inst, Orlando, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9514
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program
    Prelaj, A.
    Bottiglieri, A.
    Proto, C.
    Lo Russo, G.
    Signorelli, D.
    Ferrara, R.
    Galli, G.
    De Toma, A.
    Viscardi, G.
    Brambilla, M.
    Lobefaro, R.
    Manglaviti, S.
    Occhipinti, M.
    Labianca, A.
    Gallucci, R.
    Molino, G.
    Zilembo, N.
    Greco, F. G.
    Torri, V.
    Garassino, M. C.
    ANNALS OF ONCOLOGY, 2020, 31 : S882 - S882
  • [32] Mobocertinib in EGFR Exon 20 InsertionePositive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy
    Spira, A.
    Ramalingam, S.
    Neal, J.
    Piotrowska, Z.
    Mekhail, T.
    Tsao, A.
    Gentzler, R.
    Riely, G.
    Bazhenova, L.
    Gadgeel, S.
    Nguyen, D.
    Johnson, M.
    Vincent, S.
    Jin, S.
    Griffin, C.
    Bunn, V.
    Lin, J.
    Churchill, E.
    Mehta, M.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S873 - S874
  • [33] Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations
    Girard, N.
    Bazhenova, L.
    Minchom, A.
    Ou, S.
    Gadgeel, S.
    Trigo, J.
    Viteri, S.
    Li, G.
    Mahadevia, P.
    Londhe, A.
    Backenroth, D.
    Li, T.
    Bauml, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S145 - S146
  • [34] RETROSPECTIVE STUDY OF ERLOTINIB IN PREVIOUSLY TREATED NSCLC PATIENTS WITH WILD-TYPE EGFR
    Nakahara, Yoshiro
    Hosomi, Yukio
    Yomota, Makiko
    Okuma, Yusuke
    Takagi, Yusuke
    Iguchi, Mari
    Okamura, Tatsuru
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S490 - S490
  • [35] In Vivo, Ex Vivo and Early Clinical Activity of EGFR Monoclonal Antibody and Osimertinib in EGFR Exon 20 Insertion NSCLC
    Riess, J.
    Floch, N.
    Mack, P.
    Martin, M.
    Vang, D.
    Smith, P.
    Cross, D.
    Cheng, M.
    Keck, J.
    Groshen, S.
    Rabin, M.
    Padda, S.
    Oxnard, G.
    Sands, J.
    Ramchandran, K.
    Koczywas, M.
    Moscow, J.
    Janne, P.
    Lara, P.
    Newman, E.
    Gandara, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S282 - S282
  • [36] Predictive ability of circulating tumor DNA by Guardant360 in poziotinib-treated patients with NSCLC harboring HER2 exon 20 insertion mutations
    Thiagalingam, Arunthi
    Lakshmikanthan, Sribalaji
    Mak, Allysia J.
    Shell, Scott A.
    Leu, Sharon
    Washington, Rocky
    Dreiling, Lyndah
    Bhat, Gajanan
    Lebel, Francois
    Barrett, John A.
    CANCER RESEARCH, 2022, 82 (12)
  • [37] Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC
    van Veggel, Bianca
    de Langen, Adrianus J.
    Hashemi, Sayed M. S.
    Monkhorst, Kim
    Heideman, Danielle A. M.
    Thunnissen, Erik
    Smit, Egbert F.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1222 - 1226
  • [38] Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
    Ou, Sai-Hong Ignatius
    Lin, Huamao M.
    Hong, Jin-Liern
    Yin, Yu
    Jin, Shu
    Lin, Jianchang
    Mehta, Minal
    Nguyen, Danny
    Neal, Joel W.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (10):
  • [39] Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment
    Yang, J. C. -H.
    Wang, M.
    Mitchell, P.
    Fang, J.
    Nian, W.
    Chiu, C-H.
    Zhou, J.
    Zhao, Y.
    Su, W. -C.
    Camidge, R.
    Yang, T. -Y.
    Zhu, V.
    Millward, M.
    Fan, Y.
    Huang, W. -T.
    Cheng, Y.
    Jiang, L.
    Brungs, D.
    Bazhenova, L. B.
    Lee, C. K.
    Gao, B.
    Zheng, L.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S410 - S411
  • [40] Preliminary safety and activity of CLN-081 in NSCLC with EGFR exon 20 insertion mutations (Ins20)
    Piotrowska, Z.
    Nguyen, D.
    Koczywas, M.
    Tchekmedyian, N.
    Clancy, M. S.
    Witter, D.
    Page, A.
    Zawel, L.
    Yu, H. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S862 - S863
12345